Physician profile
Ashley E Holdridge
NPI 1790003549
$367,906.04
in general payments reported to CMS, 2019-2025
13 companies · $41K in 2025
The $41K reported for 2025 was more than what 96% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $100K · 2020: $39K · 2021: $66K · 2022: $66K · 2023: $31K · 2024: $26K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Honoraria: $33K · Consulting Fee: $9,900 · Travel and Lodging: $8,210 · Food and Beverage: $3,428 · Education: $16.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $42,981.25 |
| Honoraria | $32,547.50 |
| Consulting Fee | $9,899.68 |
| Travel and Lodging | $8,210.45 |
| Food and Beverage | $3,427.55 |
| Education | $16.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $105,613.15 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $85,691.74 | 2019-2023 | Ajovy |
| Lundbeck LLC | $66,875.77 | 2020-2025 | Vyepti |
| Lilly USA, LLC | $37,848.06 | 2019-2024 | Emgality |
| Amgen INC. | $35,868.63 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $17,250.43 | 2020-2021 | |
| Allergan, INC. | $14,482.18 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $3,950.00 | 2022 | |
| Supernus Pharmaceuticals, INC. | $192.52 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $49.51 | 2019 | |
| Promius Pharma LLC | $38.34 | 2019 | |
| Amneal Pharmaceuticals LLC | $26.66 | 2019 | |
| Pfizer INC. | $19.05 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Holdridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.